TY - JOUR
T1 - Characteristics of donor-specific antibodies associated with antibody-mediated rejection in lung transplantation
AU - Foch Lung Transplantation Group
AU - Roux, Antoine
AU - Le Lan, Ines Bendib
AU - Holifanjaniaina, Sonia
AU - Thomas, Kimberly A.
AU - Picard, Clément
AU - Grenet, Dominique
AU - De Miranda, Sandra
AU - Douvry, Benoit
AU - Beaumont-Azuar, Laurence
AU - Sage, Edouard
AU - Devaquet, Jérôme
AU - Cuquemelle, Elise
AU - Guen, Morgan Le
AU - Suberbielle, Caroline
AU - Gautreau, Chantal
AU - Stern, Marc
AU - Rossetti, Maura
AU - Hamid, Abdul Monem
AU - Parquin, Francois
AU - Miranda, Sandra De
AU - Le Bourdelles, Geneviève
AU - Neveu, Hélène
AU - Usturoi, Daniela
AU - Chapelier, Alain
AU - Puyo, Philippe
AU - Bonnette, Pierre
AU - Bellier, Jocelyn
AU - Glorion, Mathieu
AU - Abou-Taam, Salam
AU - Gonin, François
AU - Ngo, Triet
AU - Cerf, Charles
AU - Trebbia, Grégoire
AU - Soummer, Alexis
AU - Lanceleur, Anthony
AU - Bouferrache, Koceila
AU - Courtier, David
AU - Caille, Vincent
AU - Larbi, Anne Gaëlle Si
AU - Fischler, Marc
AU - Le Guen, Morgan
AU - Dumans-Nizard, Virginie
AU - Szekely, Barbara
AU - Michel-Cherqui, Mireille
AU - Marandon, Jean Yves
AU - Liu, Ngai
AU - Ley, Léa
AU - Bresson, Julie
AU - Felten, Marie Louise
AU - Binczak, Marie
N1 - Publisher Copyright:
© 2017 Roux, Bendib Le Lan, Holifanjaniaina, Thomas, Picard, Grenet, De Miranda, Douvry, Beaumont-Azuar, Sage, Devaquet, Cuquemelle, Le Guen, Suberbielle, Gautreau, Stern, Rossetti, Hamid and Parquin.
PY - 2017/1/1
Y1 - 2017/1/1
N2 - Although donor-specific anti-human leukocyte antigen (HLA) antibodies (DSAs) are frequently found in recipients after lung transplantation (LT), the characteristics of DSA which influence antibody-mediated rejection (AMR) in LT are not fully defined. We retrospectively analyzed 206 consecutive LT patients of our center (2010-2013). DSAs were detected by using luminex single antigen beads assay and mean fluorescence intensity was assessed. Within the study population, 105 patients had positive DSA. Patients with and without AMR (AMR Pos , n = 22, and AMR Neg , n = 83, respectively) were compared. AMR Pos patients had significantly greater frequencies of anti-HLA DQ DSA (DQ DSA) than AMR Neg patients (95 vs 58%, respectively, p < 0.0001). Compared to AMR Neg patients, AMR Pos patients had higher DQ DSA sum MFI [7,332 (2,067-10,213) vs 681 (0-1,887), p < 0.0001]. DQ DSA when associated with AMR, had more frequent graft loss and chronic lung allograft dysfunction (CLAD). These data suggest (i) that DSA characteristics clearly differ between AMR Pos and AMR Neg patients and (ii) the deleterious impact of DQ DSA on clinical outcome.
AB - Although donor-specific anti-human leukocyte antigen (HLA) antibodies (DSAs) are frequently found in recipients after lung transplantation (LT), the characteristics of DSA which influence antibody-mediated rejection (AMR) in LT are not fully defined. We retrospectively analyzed 206 consecutive LT patients of our center (2010-2013). DSAs were detected by using luminex single antigen beads assay and mean fluorescence intensity was assessed. Within the study population, 105 patients had positive DSA. Patients with and without AMR (AMR Pos , n = 22, and AMR Neg , n = 83, respectively) were compared. AMR Pos patients had significantly greater frequencies of anti-HLA DQ DSA (DQ DSA) than AMR Neg patients (95 vs 58%, respectively, p < 0.0001). Compared to AMR Neg patients, AMR Pos patients had higher DQ DSA sum MFI [7,332 (2,067-10,213) vs 681 (0-1,887), p < 0.0001]. DQ DSA when associated with AMR, had more frequent graft loss and chronic lung allograft dysfunction (CLAD). These data suggest (i) that DSA characteristics clearly differ between AMR Pos and AMR Neg patients and (ii) the deleterious impact of DQ DSA on clinical outcome.
KW - Antibody mediated rejection
KW - Clinical outcome
KW - Donor-specific antibodies
KW - HLA
KW - Lung transplant
UR - http://www.scopus.com/inward/record.url?scp=85048514807&partnerID=8YFLogxK
U2 - 10.3389/fmed.2017.00155
DO - 10.3389/fmed.2017.00155
M3 - Article
AN - SCOPUS:85048514807
SN - 2296-858X
VL - 4
JO - Frontiers in Medicine
JF - Frontiers in Medicine
IS - OCT
M1 - 155
ER -